Clinical trial
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
NCT04616209
Study timeline
Study start (actual)2020-11-15Date precision: day
Registry last updated2025-02-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Cancerunresolved
Interventions
donor-derived NK cell infusionBIOLOGICAL
Sponsors & collaborators
Precision Biotech Taiwan Corp.lead sponsor
Tri-Service General Hospital (TSGH)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04616209 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.